Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)
- Previous Close
16.09 - Open
15.15 - Bid 16.11 x --
- Ask 16.16 x --
- Day's Range
15.58 - 16.17 - 52 Week Range
12.68 - 33.00 - Volume
2,639,100 - Avg. Volume
2,781,319 - Market Cap (intraday)
1.936B - Beta (5Y Monthly) --
- PE Ratio (TTM)
52.03 - EPS (TTM)
0.31 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 25, 2022
- 1y Target Est
--
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals, pharmaceutical preparations, and synthetic chemicals in China. It offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. The company also provides technical transferring services. In addition, it offers supply chain management services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China.
www.hicin.cn/page1/index1--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 300584.SZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300584.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300584.SZ
Valuation Measures
Market Cap
1.94B
Enterprise Value
2.19B
Trailing P/E
51.68
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.83
Price/Book (mrq)
1.93
Enterprise Value/Revenue
4.33
Enterprise Value/EBITDA
44.80
Financial Highlights
Profitability and Income Statement
Profit Margin
7.41%
Return on Assets (ttm)
2.63%
Return on Equity (ttm)
3.82%
Revenue (ttm)
505.19M
Net Income Avi to Common (ttm)
37.46M
Diluted EPS (ttm)
0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
19.87M
Total Debt/Equity (mrq)
27.03%
Levered Free Cash Flow (ttm)
-163.68M
Company Insights: 300584.SZ
300584.SZ does not have Company Insights